221 related articles for article (PubMed ID: 34844413)
21. Identification of therapeutic effect of glucagon-like peptide 1 in the treatment of STZ-induced diabetes mellitus in rats by restoring the balance of intestinal flora.
Yuan X; Ni H; Chen X; Feng X; Wu Q; Chen J
J Cell Biochem; 2018 Dec; 119(12):10067-10074. PubMed ID: 30129059
[TBL] [Abstract][Full Text] [Related]
22. Intervention effect of Potentilla discolor-Euonymus alatus on intestinal flora of type 2 diabetes mellitus rats.
He SY; Qiu XM; Wang YQ; Su ZQ; Zhang BY; Wen Z; Yang YF; Xing BF; Hong M; Liao R
Eur Rev Med Pharmacol Sci; 2022 Dec; 26(24):9062-9071. PubMed ID: 36591818
[TBL] [Abstract][Full Text] [Related]
23. Gut microbiome: New perspectives for type 2 diabetes prevention and treatment.
Li SX; Guo Y
World J Clin Cases; 2023 Nov; 11(31):7508-7520. PubMed ID: 38078135
[TBL] [Abstract][Full Text] [Related]
24. The Relationship between the Gut Microbiome and Metformin as a Key for Treating Type 2 Diabetes Mellitus.
Lee CB; Chae SU; Jo SJ; Jerng UM; Bae SK
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808194
[TBL] [Abstract][Full Text] [Related]
25. Gut Microbiota: An Important Player in Type 2 Diabetes Mellitus.
Zhou Z; Sun B; Yu D; Zhu C
Front Cell Infect Microbiol; 2022; 12():834485. PubMed ID: 35242721
[TBL] [Abstract][Full Text] [Related]
26. Interactions Between Gut Microbiota, Host, and Herbal Medicines: A Review of New Insights Into the Pathogenesis and Treatment of Type 2 Diabetes.
Zheng Y; Gou X; Zhang L; Gao H; Wei Y; Yu X; Pang B; Tian J; Tong X; Li M
Front Cell Infect Microbiol; 2020; 10():360. PubMed ID: 32766169
[TBL] [Abstract][Full Text] [Related]
27. Relationship between gut microbiota, probiotics, and type 2 diabetes mellitus.
Salgaço MK; Oliveira LGS; Costa GN; Bianchi F; Sivieri K
Appl Microbiol Biotechnol; 2019 Dec; 103(23-24):9229-9238. PubMed ID: 31664483
[TBL] [Abstract][Full Text] [Related]
28. Prevention and treatment strategies for type 2 diabetes based on regulating intestinal flora.
Xie D; Zhao X; Chen M
Biosci Trends; 2021 Nov; 15(5):313-320. PubMed ID: 34565781
[TBL] [Abstract][Full Text] [Related]
29. Gut microbiota-derived metabolites as key actors in type 2 diabetes mellitus.
Du L; Li Q; Yi H; Kuang T; Tang Y; Fan G
Biomed Pharmacother; 2022 May; 149():112839. PubMed ID: 35325852
[TBL] [Abstract][Full Text] [Related]
30. Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
Hare KJ
Dan Med Bull; 2010 Sep; 57(9):B4181. PubMed ID: 20816021
[TBL] [Abstract][Full Text] [Related]
31. Effects of the synbiotic composed of mangiferin and
Meng F; Zhang F; Meng M; Chen Q; Yang Y; Wang W; Xie H; Li X; Gu W; Yu J
Front Microbiol; 2023; 14():1158652. PubMed ID: 37152739
[TBL] [Abstract][Full Text] [Related]
32. Coix seed polysaccharides alleviate type 2 diabetes mellitus via gut microbiota-derived short-chain fatty acids activation of IGF1/PI3K/AKT signaling.
Xia T; Liu CS; Hu YN; Luo ZY; Chen FL; Yuan LX; Tan XM
Food Res Int; 2021 Dec; 150(Pt A):110717. PubMed ID: 34865748
[TBL] [Abstract][Full Text] [Related]
33. [Research Progress on the Role of
Yang Y; Wu XK
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Feb; 45(1):108-116. PubMed ID: 36861163
[TBL] [Abstract][Full Text] [Related]
34. Gut Bacterial Characteristics of Patients With Type 2 Diabetes Mellitus and the Application Potential.
Que Y; Cao M; He J; Zhang Q; Chen Q; Yan C; Lin A; Yang L; Wu Z; Zhu D; Chen F; Chen Z; Xiao C; Hou K; Zhang B
Front Immunol; 2021; 12():722206. PubMed ID: 34484230
[TBL] [Abstract][Full Text] [Related]
35. Fourteen composite probiotics alleviate type 2 diabetes through modulating gut microbiota and modifying M1/M2 phenotype macrophage in db/db mice.
Wang Y; Wu Y; Sailike J; Sun X; Abuduwaili N; Tuoliuhan H; Yusufu M; Nabi XH
Pharmacol Res; 2020 Nov; 161():105150. PubMed ID: 32818655
[TBL] [Abstract][Full Text] [Related]
36. The predicted mechanisms and evidence of probiotics on type 2 diabetes mellitus (T2DM).
Bajinka O; Sylvain Dovi K; Simbilyabo L; Conteh I; Tan Y
Arch Physiol Biochem; 2023 Jan; ():1-16. PubMed ID: 36630122
[TBL] [Abstract][Full Text] [Related]
37. The role of enteric dysbacteriosis and modulation of gut microbiota in the treatment of inflammatory bowel disease.
Niu W; Yang F; Fu Z; Dong Y; Zhang Z; Ju J
Microb Pathog; 2022 Apr; 165():105381. PubMed ID: 34974123
[TBL] [Abstract][Full Text] [Related]
38. New Insights of Anti-Hyperglycemic Agents and Traditional Chinese Medicine on Gut Microbiota in Type 2 Diabetes.
Chen Y; Wang M
Drug Des Devel Ther; 2021; 15():4849-4863. PubMed ID: 34876807
[TBL] [Abstract][Full Text] [Related]
39. Targeting the Intestinal Microbiota to Prevent Type 2 Diabetes and Enhance the Effect of Metformin on Glycaemia: A Randomised Controlled Pilot Study.
Palacios T; Vitetta L; Coulson S; Madigan CD; Lam YY; Manuel R; Briskey D; Hendy C; Kim JN; Ishoey T; Soto-Giron MJ; Schott EM; Toledo G; Caterson ID
Nutrients; 2020 Jul; 12(7):. PubMed ID: 32660025
[TBL] [Abstract][Full Text] [Related]
40. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
